Osteoprotegerin levels in patients with severe mental disorders.

BACKGROUND Severe mental disorders are associated with elevated levels of inflammatory markers. In the present study, we investigated whether osteoprotegerin (OPG), a member of the tumour necrosis factor receptor family involved in calcification and inflammation, is elevated in patients with severe mental disorders. METHODS We measured the plasma levels of OPG in patients with severe mental disorders (n = 312; 125 with bipolar disorder and 187 with schizophrenia) and healthy volunteers (n = 239). RESULTS The mean plasma levels of OPG were significantly higher in patients than in controls (t531 = 2.6, p = 0.01), with the same pattern in bipolar disorder and schizophrenia. The increase was significant after adjustment for possible confounding variables, including age, sex, ethnic background, alcohol consumption, liver and kidney function, diabetes, cardiovascular disease, autoimmune diseases and levels of cholesterol, glucose and C-reactive protein. LIMITATIONS Owing to the cross-sectional design, it is difficult to determine causality. CONCLUSION Our results indicate that elevated OPG levels are associated with severe mental disorders and suggest that mechanisms related to calcification and inflammation may play a role in disease development.

• Publication year

  2010

• Venue

  Journal of Psychiatry & Neuroscience

• Publication date

  2010-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1503/jpn.090088PMID 20569643PMCID PMC2928283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteoprotegerin concentrations and prognosis in acute ischaemic stroke

  2010cited by this paper
• The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder

  2010cited by this paper
• Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-&kgr;B Ligand and Risk for Coronary Events: A Nested Case–Control Approach in the Prospective EPIC-Norfolk Population Study 1993–2003

  2009cited by this paper
• Matrix Metalloproteinase-9 Gene and Bipolar Mood Disorder

  2009cited by this paper
• Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose.

  2009cited by this paper
• Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.

  2009cited by this paper
• Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans

  2009cited by this paper
• Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.

  2009cited by this paper
• Evidence for a cytokine model of cognitive function.

  2009cited by this paper
• Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia.

  2009cited by this paper
• Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice.

  2009cited by this paper
• The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review.

  2008cited by this paper
• The risk for schizophrenia from childhood and adult infections.

  2008cited by this paper
• Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes.

  2008influential reference
• TNF-alpha as a molecular target in bipolar disorder.

  2008cited by this paper
• Psychiatric genetics: progress amid controversy

  2008cited by this paper
• Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

  2008cited by this paper
• Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study.

  2008cited by this paper
• Stress hormones and immune function.

  2008cited by this paper
• Relationship of Calcification of Atherosclerotic Plaque and Arterial Stiffness to Bone Mineral Density and Osteoprotegerin in Postmenopausal Women Referred for Osteoporosis Screening

  2008cited by this paper
• TRAIL and osteoprotegerin: a role in endothelial physiopathology?

  2008cited by this paper
• Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

  2008cited by this paper
• Inflammation, Glutamate, and Glia in Depression: A Literature Review

  2008cited by this paper
• A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes.

  2008cited by this paper
• Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.

  2007cited by this paper
• Polymorphisms at the Osteoprotegerin and Interleukin-6 Genes in Relation to First-Ever Stroke

  2007cited by this paper
• Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

  2007cited by this paper
• The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption.

  2007cited by this paper
• Progressive gray matter loss in patients with bipolar disorder.

  2007cited by this paper
• Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia

  2007cited by this paper
• Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder.

  2007cited by this paper
• Inflammatory biomarkers are associated with total brain volume

  2007cited by this paper
• RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases

  2007cited by this paper
• The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study.

  2007cited by this paper
• Generalizability studies of the Global Assessment of Functioning-Split version.

  2007cited by this paper
• What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia.

  2007cited by this paper
• A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

  2007cited by this paper
• Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers.

  2007cited by this paper
• Cytokines in schizophrenia and the effects of antipsychotic drugs.

  2006cited by this paper
• Bone Mineral Density, Bone Turnover, and Osteoprotegerin in Depressed Women With and Without Borderline Personality Disorder

  2006cited by this paper
• Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure

  2005cited by this paper
• Theories of schizophrenia: a genetic-inflammatory-vascular synthesis

  2005cited by this paper
• Decreased osteoprotegerin and increased bone turnover in young female patients with major depressive disorder and a lifetime history of anorexia nervosa

  2005cited by this paper
• Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK.

  2004cited by this paper
• Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel.

  2004cited by this paper
• Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications.

  2003cited by this paper
• Cytokines role in neurodegenerative events.

  2003cited by this paper
• Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range.

  2002cited by this paper
• Excess mortality in bipolar and unipolar disorder in Sweden.

  2001cited by this paper
• Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

  2001cited by this paper
• Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis.

  2001cited by this paper
• Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.

  2000cited by this paper
• Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in Osteoblasts.

  2000cited by this paper
• Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study.

  1994cited by this paper

• Distinct cytokine-producing dendritic cell profiles in females and males with major depressive disorder.

  2026cites this paper
• Plasma Osteoprotegerin and Cognitive Impairment after Ischemic Stroke.

  2025cites this paper
• Cognitive and inflammatory heterogeneity in severe mental illness: Translating findings from blood to brain

  2023cites this paper
• Therapeutic Effects of a Novel Form of Biotin on Propionic Acid-Induced Autistic Features in Rats

  2022cites this paper
• Mechanism of Bone Metabolism Interruption Due to High Intensity Physical Exercise

  2020cites this paper
• Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review

  2018cites this paper
• Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders

  2018cites this paper
• Persistent increase in TNF and IL‐1 markers in severe mental disorders suggests trait‐related inflammation: a one year follow‐up study

  2017cites this paper
• Inflammatory evidence for the psychosis continuum model.

  2016cites this paper
• Association between cytokine levels, verbal memory and hippocampus volume in psychotic disorders and healthy controls

  2016influential citation
• Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder

  2015cites this paper
• General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases.

  2015cites this paper
• Association between altered brain morphology and elevated peripheral endothelial markers--implications for psychotic disorders.

  2015cites this paper
• C-reactive protein alterations in bipolar disorder: a meta-analysis.

  2015cites this paper
• Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls.

  2015cites this paper
• Changes in gene expression within the extended amygdala following binge-like alcohol drinking by adolescent alcohol-preferring (P) rats.

  2014cites this paper
• C-reactive protein levels in schizophrenia: a review and meta-analysis.

  2014cites this paper
• Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci

  2014cites this paper
• Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder.

  2013cites this paper
• Bone mineral density and bone metabolism in patients with major depressive disorder without somatic comorbidities.

  2013cites this paper
• Endothelial and inflammation markers in schizophrenia and bipolar disorder

  2013cites this paper
• Up-regulation of NOTCH4 gene expression in bipolar disorder.

  2012cites this paper
• Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome.

  2012cites this paper
• Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.

  2012cites this paper
• Inflammatory profile in schizophrenia and bipolar disorder

  2012cites this paper
• Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia.

  2011cites this paper